Clinical Research Directory

Inclusion criteria * Patients with multiple myeloma: * Age 18 years or older at diagnosis * Diagnosed symptomatic multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria * Completion of four cycles of first-line induction therapy * Availability of a stored genomic DNA sample of sufficient quantity and quality for next-generation sequencing * Availability of baseline clinical data (Durie-Salmon stage, ISS stage, ECOG performance status, laboratory data) and treatment response and survival data * Written informed consent for the use of biological samples and clinical data for genetic research Healthy controls: * Age 18 years or older * No known hematological disease, malignancy, or chronic inflammatory or autoimmune disease * Availability of a stored genomic DNA sample of sufficient quantity and quality for next-generation sequencing * Written informed consent for the use of biological samples for genetic research Exclusion Criteria: * Diagnosis of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, solitary plasmacytoma, plasma cell leukemia, POEMS syndrome, or primary AL amyloidosis without multiple myeloma * History of another malignancy, except adequately treated non-melanoma skin cancer or carcinoma in situ * Insufficient or degraded DNA sample, or failed sequencing quality control * First-degree relationship with another participant already included in the study